Sarepta Therapeutics, Inc. (LON:0L35)
38.38
+1.19 (3.19%)
At close: May 20, 2025
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $744.86M USD in the quarter ending March 31, 2025, with 80.15% growth. This brings the company's revenue in the last twelve months to $2.23B, up 59.15% year-over-year. In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth.
Revenue (ttm)
$2.23B
Revenue Growth
+59.15%
P/S Ratio
1.64
Revenue / Employee
$1.63M
Employees
1,372
Market Cap
2.84B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Sarepta Therapeutics News
- 7 days ago - Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - Business Wire
- 7 days ago - Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 - Business Wire
- 10 days ago - Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy - Business Wire
- 13 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT - Accesswire
- 14 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT - GlobeNewsWire
- 14 days ago - Top 3 Health Care Stocks That Are Preparing To Pump This Quarter - Benzinga
- 14 days ago - Sarepta Therapeutics to Present at the BofA Securities Health Care Conference - Business Wire
- 15 days ago - SA analyst downgrades: BTI, HSY, SRPT, HIMS, S - Seeking Alpha